Protean BioDiagnostics is currently recruiting patients to participate in an important clinical trial that could forever improve breast cancer diagnostics.
For those who have undergone treatment for breast cancer, metastasis and disease recurrence are of grave concern. Unfortunately, diagnosing metastases means undergoing painful and invasive biopsy procedures.
We are developing advanced liquid biopsy technology that could replace invasive biopsies with simple blood draws, by looking for evidence of new tumors that may be hiding in your blood. This trial will investigate whether the blood draws are a viable alternative to traditional biopsies, which is a critical step towards making liquid biopsies available to women everywhere.
Who qualifies for the trial?
Qualifying participants must meet all of the following criteria:
Adult aged 18 years and up
Diagnosed with breast cancer at least 6 months ago
Suspected recurrent metastasis
Have blood drawn for liquid biopsy before tissue biopsy taken or beginning treatment for metastases
Willing and able to give informed consent for participating in the trial
Located in Canada or the US
For full information on inclusion and exclusion criteria, and to find out if you qualify, please contact info@proteanbiodx.com
What is involved in participating in the trial?
Two tubes of blood will be drawn before your traditional biopsy procedure (up to 30 days prior). The blood samples will be run through an advanced testing protocol, and the results will be compared with your biopsy results. Consenting participants will have additional blood drawn 6 months after the initial draw. A detailed pathology report on your tissue biopsy samples will be provided to your primary care physician.
Important: Decisions about your treatment will not be made based on the liquid biopsy results.
Can I find more information about the trial?
Full details are available on the clinicaltrials.gov trial listing:
https://clinicaltrials.gov/ct2/show/NCT04962529
For more information on enrollment, please fill out the following form or email us at info@proteanbiodx.com
Dr. Anthony M. Magliocco, MD FRCPC FCAP
President and CEO
Dr. Magliocco is a Physician, Scientist, and Professor of Oncology and Pathology. He is an internationally recognized cancer expert with experience in breast cancer research, diagnosis and treatment. He was Chair of Pathology at the Moffitt Cancer Center in Tampa, Florida between 2011-2019. Previously, he was Director of Pathology at the Tom Baker Cancer Center and directed the implementation of HER2 testing in Canada. More recently he is focused on improving diagnostic services for women with breast cancer and has founded Protean BioDiagnostics and created the Oncology MAPS™ system to help community based oncologists access precision diagnostic lab services. Dr. Magliocco’s vision is for all breast cancer patients to have access to the precision diagnostic services they need for optimal treatment of their cancer.